特发性颅内高压中潜在可改变的风险因素：体重。
The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension: Body Weight.
作者信息
Mollan Susan P, Tahrani Abd A, Sinclair Alexandra J
机构信息
Birmingham Neuro-Ophthalmology (SPM), Queen Elizabeth Hospital; Institute of Metabolism and Systems Research (AAT), College of Medical and Dental Sciences, University of Birmingham; Department of Diabetes and Endocrinology (AAT), Queen Elizabeth Hospital, Birmingham; Metabolic Neurology (AJS), Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham; and Department of Neurology (AJS), University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, United Kingdom.
出版信息
Neurol Clin Pract. 2021 Aug;11(4):e504-e507. doi: 10.1212/CPJ.0000000000001063.
PURPOSE OF REVIEW
Idiopathic intracranial hypertension (IIH) prevalence increased in conjunction with rising obesity rates. Here, we highlight the importance of weight management in IIH and introduce glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) as potential treatment strategy for IIH.
RECENT FINDINGS
Weight gain is a risk factor for IIH, and weight loss (via any treatment strategy) plays a key role in IIH management. GLP-1 is an incretin secreted by the distal small intestine in response to a meal. GLP-1 RAs have been shown to improve glycaemic control (no hypoglycaemia) and lower body weight in patients with and without type 2 diabetes. The choroid plexus has been found to express GLP-1 receptors, and treatment with a GLP-1 RA significantly reduces CSF secretion in vitro and intracranial pressure (ICP) in rodents.
SUMMARY
New research evaluating the pathophysiology of IIH supports GLP-1 RA as a potential treatment for IIH via weight loss dependent and independent mechanism to directly reduce ICP.
综述目的
特发性颅内高压（IIH）的患病率随着肥胖率的上升而增加。在此，我们强调体重管理在IIH中的重要性，并介绍胰高血糖素样肽1（GLP-1）受体激动剂（RAs）作为IIH的潜在治疗策略。
最新发现
体重增加是IIH的一个危险因素，体重减轻（通过任何治疗策略）在IIH管理中起关键作用。GLP-1是远端小肠在进食后分泌的一种肠促胰岛素。已证明GLP-1 RAs可改善血糖控制（无低血糖），并降低2型糖尿病患者和非2型糖尿病患者的体重。已发现脉络丛表达GLP-1受体，用GLP-1 RA治疗可在体外显著减少脑脊液分泌，并降低啮齿动物的颅内压（ICP）。
总结
评估IIH病理生理学的新研究支持GLP-1 RA作为IIH的潜在治疗方法，其通过依赖体重减轻和独立于体重减轻的机制直接降低ICP。
Zotero 插件